Current therapeutic agents and anesthetic considerations for diabetes mellitus / 대한마취과학회지
Korean Journal of Anesthesiology
;
: 195-202, 2012.
Article
in English
| WPRIM
| ID: wpr-187715
ABSTRACT
As the incidence of diabetes mellitus (DM) continues to increase worldwide, more diabetic patients will be presented for surgery and anesthesia. This increase of DM is a consequence of the rise in new patients of type 2 DM, and is likely attributable to rapid economic development, improved living standards, aging population, obesity, and lack of exercise. The primary goal of management in DM is to delay, or prevent the macro- and microvascular complications by achieving good glycemic control. More understanding of the pathophysiology of DM has contributed to the advance of new pharmacological approaches. In addition to the conventional therapy for DM, glucagon-like peptide-1 (GLP-1) mimetics, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones (TZDs), and insulin analogues are currently available effective hypoglycemic agents for the management of the patients with DM in the perioperative period and also consider the adverse effects of newly introduced agents that need more clinical observations.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Socioeconomic Factors
/
Aging
/
Economic Development
/
Incidence
/
Thiazolidinediones
/
Diabetes Mellitus
/
Glucagon-Like Peptide 1
/
Perioperative Period
/
Glucose
/
Hypoglycemia
Type of study:
Practice guideline
/
Incidence study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Korean Journal of Anesthesiology
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS